KALV - KalVista Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

KalVista Pharmaceuticals, Inc.

55 Cambridge Parkway
Suite 901 East
Cambridge, MA 02142
United States

Full Time Employees45

Key Executives

NameTitlePayExercisedYear Born
Mr. Thomas Andrew CrockettCEO & Director869.5kN/A1975
Mr. Benjamin L. PalleikoChief Bus. Officer & CFO569.15kN/A1966
Dr. Edward P. FeenerChief Scientific Officer506kN/A1960
Leah MonteiroDirector of Corp. Communications & Investor RelationsN/AN/AN/A
Ms. Rachel MortenHead of Regulatory Affairs and QAN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE; and KVD824, an oral plasma kallikrein inhibitor that is in Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.

Corporate Governance

KalVista Pharmaceuticals, Inc.’s ISS Governance QualityScore as of December 5, 2019 is 9. The pillar scores are Audit: 3; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.